PMDA drug package insert
ベニジピン塩酸塩錠2mg「NS」
PMDA Prescription drug · 日新製薬株式会社 · package insert Sep 29, 2023
Key facts
| Brand names | ベニジピン塩酸塩錠2mg「NS」, ベニジピン塩酸塩錠4mg「NS」, ベニジピン塩酸塩錠8mg「NS」 |
|---|---|
| Nonproprietary names | ベニジピン塩酸塩 |
| Companies | 製造販売元／日新製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 高血圧症・狭心症治療剤（持続性Ca拮抗薬） |
| Therapeutic category codes | 872179 |
| YJ codes | 2171021F1261, 2171021F2284, 2171021F3264 |
| Approval numbers | 22700AMX00036, 22700AMX00037, 22700AMX00035 |
| Package insert edition | 第1版 |
| Package insert date | Sep 29, 2023 |
| PMDA document key | 530113_2171021F1261_1 |
| PMDA company code | 530113 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: